IBO vs ANRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IBO Captures Institutional Edge (3โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Impact BioMedical, Inc. (IBO) driven by superior Valuation, Growth & Margin, Momentum & Technical while ANRO counters with relative strength in Options & Structure. Fundamentally, IBO trades at N/M Forward P/E with -12621.0% operating margin (+16.7% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ANRO sits in CONSOLIDATION (8th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IBO | ANRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $44.4M | $1.2B | Larger Scale | ANRO |
| Trailing P/E Ratio Valuation | 0.4x | N/M | Lower Multiple | IBO |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +16.7% | +0.0% | Higher Growth | IBO |
| Operating Margin (TTM) Profitability | -12621.0% | 0.0% | Higher Margin | ANRO |
| Net Profit Margin Profitability | 4247.4% | 0.0% | Higher Margin | IBO |
| Return on Equity (ROE) Capital Efficiency | 71.2% | -46.7% | Higher ROE | IBO |
| 52-Week Range Position Momentum | 67% ($0โ$7) | 61% ($11โ$37) | Stronger Trend | IBO |
| Beta / 30D Volatility Risk Regime | -6.72ฮฒ ยท 120% Vol | 1.95ฮฒ ยท 90% Vol | Lower Realized Risk | ANRO |
| Unified Institutional Score Composite Signal | 36.8 / 100 (SELL) | 29.3 / 100 (SELL) | Higher Composite | IBO |